CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - TSX:CPH - CA17253X1050 - Common Stock
17.04 CAD
+0.69 (+4.22%)
Taking everything into account, CPH scores 6 out of 10 in our fundamental rating. CPH was compared to 34 industry peers in the Pharmaceuticals industry. While CPH has a great profitability rating, there are some minor concerns on its financial health. CPH is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year CPH was profitable.
In the past year CPH had a positive cash flow from operations.
In the past 5 years CPH has always been profitable.
CPH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CPH has a better Return On Assets (7.97%) than 94.12% of its industry peers.
CPH's Return On Equity of 11.10% is amongst the best of the industry. CPH outperforms 88.24% of its industry peers.
With an excellent Return On Invested Capital value of 5.17%, CPH belongs to the best of the industry, outperforming 85.29% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CPH is in line with the industry average of 7.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 11.1% | ||
| ROIC | 5.17% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
CPH's Profit Margin of 25.52% is amongst the best of the industry. CPH outperforms 100.00% of its industry peers.
In the last couple of years the Profit Margin of CPH has grown nicely.
CPH's Operating Margin of 20.32% is amongst the best of the industry. CPH outperforms 88.24% of its industry peers.
In the last couple of years the Operating Margin of CPH has declined.
The Gross Margin of CPH (73.79%) is better than 94.12% of its industry peers.
CPH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.32% | ||
| PM (TTM) | 25.52% | ||
| GM | 73.79% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CPH is destroying value.
Compared to 1 year ago, CPH has more shares outstanding
The number of shares outstanding for CPH has been reduced compared to 5 years ago.
CPH has a worse debt/assets ratio than last year.
2.2 Solvency
CPH has an Altman-Z score of 5.58. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
CPH's Altman-Z score of 5.58 is amongst the best of the industry. CPH outperforms 94.12% of its industry peers.
CPH has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
CPH has a Debt to Equity ratio of 0.23. This is comparable to the rest of the industry: CPH outperforms 52.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.58 |
ROIC/WACC0.57
WACC9.02%
2.3 Liquidity
A Current Ratio of 1.72 indicates that CPH should not have too much problems paying its short term obligations.
With a Current ratio value of 1.72, CPH perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
A Quick Ratio of 1.41 indicates that CPH should not have too much problems paying its short term obligations.
CPH has a Quick ratio (1.41) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 |
3. Growth
3.1 Past
CPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.31%.
CPH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.47% yearly.
Looking at the last year, CPH shows a very strong growth in Revenue. The Revenue has grown by 114.76%.
CPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.25% yearly.
EPS 1Y (TTM)-48.31%
EPS 3Y13.23%
EPS 5Y12.47%
EPS Q2Q%83.33%
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
3.2 Future
Based on estimates for the next years, CPH will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.85% on average per year.
Based on estimates for the next years, CPH will show a very strong growth in Revenue. The Revenue will grow by 21.67% on average per year.
EPS Next Y105.37%
EPS Next 2Y21.71%
EPS Next 3Y14.85%
EPS Next 5YN/A
Revenue Next Year49.11%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 26.62, which means the current valuation is very expensive for CPH.
CPH's Price/Earnings ratio is rather cheap when compared to the industry. CPH is cheaper than 82.35% of the companies in the same industry.
When comparing the Price/Earnings ratio of CPH to the average of the S&P500 Index (27.41), we can say CPH is valued inline with the index average.
CPH is valuated rather expensively with a Price/Forward Earnings ratio of 18.50.
Based on the Price/Forward Earnings ratio, CPH is valued a bit cheaper than 79.41% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.87, CPH is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.62 | ||
| Fwd PE | 18.5 |
4.2 Price Multiples
CPH's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CPH is cheaper than 61.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 18.75 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPH has an outstanding profitability rating, which may justify a higher PE ratio.
CPH's earnings are expected to grow with 14.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.25
PEG (5Y)2.13
EPS Next 2Y21.71%
EPS Next 3Y14.85%
5. Dividend
5.1 Amount
No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CPH (9/22/2025, 7:00:00 PM)
17.04
+0.69 (+4.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.35%
Inst Owner ChangeN/A
Ins Owners4.67%
Ins Owner ChangeN/A
Market Cap431.45M
Analysts77.78
Price Target17.87 (4.87%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.48%
Min EPS beat(2)-7.18%
Max EPS beat(2)36.14%
EPS beat(4)2
Avg EPS beat(4)-14.13%
Min EPS beat(4)-92.76%
Max EPS beat(4)36.14%
EPS beat(8)6
Avg EPS beat(8)67.23%
EPS beat(12)10
Avg EPS beat(12)112.56%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.9%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)2.48%
Revenue beat(4)3
Avg Revenue beat(4)31.13%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)115.89%
Revenue beat(8)5
Avg Revenue beat(8)22.37%
Revenue beat(12)5
Avg Revenue beat(12)11.03%
Revenue beat(16)5
Avg Revenue beat(16)5.52%
PT rev (1m)10.75%
PT rev (3m)9.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)46.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.62 | ||
| Fwd PE | 18.5 | ||
| P/S | 6.56 | ||
| P/FCF | N/A | ||
| P/OCF | 14.78 | ||
| P/B | 2.85 | ||
| P/tB | 18.7 | ||
| EV/EBITDA | 18.75 |
EPS(TTM)0.64
EY3.76%
EPS(NY)0.92
Fwd EY5.4%
FCF(TTM)-3.21
FCFYN/A
OCF(TTM)1.15
OCFY6.77%
SpS2.6
BVpS5.97
TBVpS0.91
PEG (NY)0.25
PEG (5Y)2.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 11.1% | ||
| ROCE | 7.18% | ||
| ROIC | 5.17% | ||
| ROICexc | 5.65% | ||
| ROICexgc | 22.78% | ||
| OM | 20.32% | ||
| PM (TTM) | 25.52% | ||
| GM | 73.79% | ||
| FCFM | N/A |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.51 | ||
| Cap/Depr | 1132.75% | ||
| Cap/Sales | 168.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 126.25% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 | ||
| Altman-Z | 5.58 |
F-Score5
WACC9.02%
ROIC/WACC0.57
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y13.23%
EPS 5Y12.47%
EPS Q2Q%83.33%
EPS Next Y105.37%
EPS Next 2Y21.71%
EPS Next 3Y14.85%
EPS Next 5YN/A
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
Revenue Next Year49.11%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
EBIT growth 1Y-12.36%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year115.21%
EBIT Next 3Y39.31%
EBIT Next 5YN/A
FCF growth 1Y-558.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.27%
OCF growth 3Y12.28%
OCF growth 5Y19.77%